2024-08-27 I-Mab Biopharma HaiPress
ROCKVILLE,Md.,Aug. 26,2024 -- I-Mab (NASDAQ: IMAB),a US-based,global,clinical-stage biotech company,exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer,today announced that management will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10,2024.
H.C. Wainwright 26th Annual Global Investment Conference
Presentation Time
Tuesday,September 10at5:00 PM ET
Presenters
Sean Fu,PhD,Interim Chief Executive Officer (CEO)
Phillip Dennis,MD,Chief Medical Officer (CMO)
Webcast link
Here
Meetings
One-on-one and small group meetings:September 9 – 10,2024
Management
Participants
Sean Fu,Interim CEO
Joe Skelton,Chief Financial Officer (CFO)
Phillip Dennis,CMO
Tyler Ehler,Senior Director,Investor Relations
The webcast will also be available under "Event Calendar" onI-Mab'sIR website
athttps://ir.i-mabbiopharma.com/
For more information,please contact your H.C. Wainwright representative.
About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based,exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville,Maryland. For more information,please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.
For more information,please contact:
Tyler Ehler
Senior Director,Investor Relations
IR@imabbio.com
Remarks by IMF Managing Director Kristalina Georgieva at the 2024 ESG Global Leaders Conference
Baidu to Report Third Quarter 2024 Financial Results on Nov 21, 2024
WuXi Biologics Launches WuXia™ RidGS for Non-Antibiotic Cell Line Development
A model for China's ecological development: Refreshing Guiyang, turning lush mountains and lucid waters into invaluable assets
Biban24 creates innovative "Doors" of opportunity for SMEs and entrepreneurs from around the world to explore
NEOM Board of Directors showcases progress with opening of Sindalah, a new luxury travel destination in the Red Sea
©copyright2009-2020Fresh life